Abstract: In some examples, a method may include depositing, from a slurry comprising particles including silicon metal, a bond coat precursor layer including the particles comprising silicon metal directly on a ceramic matrix composite substrate. The method also may include locally heating the bond coat precursor layer to form a bond coat comprising silicon metal. Additionally, the method may include forming a protective coating on the bond coat. In some examples, an article may include a ceramic matrix composite substrate, a bond coat directly on the substrate, and a protective coating on the bond coat. The bond coat may include silicon metal and a metal comprising at least one of Zr, Y, Yb, Hf, Ti, Al, Cr, Mo, Nb, Ta, or a rare earth metal.

Abstract: The invention relates to a copper-ceramic composite comprising: a ceramic substrate; and a copper or copper alloy coating on the ceramic substrate, the copper or copper alloy having grain sizes of 10 ?m to 300 ?m.

Abstract: A cohesive granular material comprises granules made of a stiff substance and having a grain size in the range from 55 ?m to 2.0 mm; an elastomeric substance connecting the granules, a Young's modulus of the elastomeric substance being at maximum 0.5 times a Young's modulus of the stiff substance; and voids between the granules, the voids being interconnected and providing a fluid permeability to the cohesive granular material.

Abstract: The glaze is prepared from the following raw materials in percentage by weight: Fire Clay 10%-25%, Feldspar 30%-40%, Sand 30%-40%, Calcium Silicate 8%-12%, Graphane (i.e., disordered crystalline and hydrogenated double bounded Carbon) 5%-15% or C-doped Boron Nitride (CBN) 5%-15%, various metal oxides as pigments and water. This glaze is applied on the standard glazing operation in the ceramic insulator manufacturing process and is fired in a controlled inert-gas atmosphere.

Abstract: A part coated in a protective coating forms a thermal barrier and includes a ceramic first layer. The protective coating further includes a second layer present on the first layer and including a majority by weight of a first feldspar mineral having a melting temperature higher than or equal to 1010° C. and presenting a thickness greater than or equal to 10 ?m.

Abstract: The fertilizers derived from date syrup may include date sugar acids chelated to at least one metal ion useful for promoting plant growth. The date acids may be synthesized from waste or non-consumable dates. The fertilizers derived from date syrup may be synthesized by extracting date syrup from dried dates, oxidizing the date syrup to obtain date acids, and chelating the date acids to at least one metal ion. The at least one metal ion may be selected from the group consisting of potassium, calcium, magnesium, copper, iron, manganese, molybdenum, zinc, and a combination thereof.

Abstract: An explosive sheet simulant that uses an ethylene vinyl acetate polymer combined with either a mixture of a boron carbide and iron oxide for X-ray attenuating properties or calcium carbonate for millimeter wave properties, wherein the components of the mixture are selected such that the sheet has a predetermined flexural modulus combined with particle density, effective atomic number, x-ray transmission properties, or millimeter wave properties.

Abstract: A smoke producing method and device of the present disclosure produces a non-incendiary, organic-polymerization based, smoke-producing reaction. Some versions of the smoke are effective carriers for capsaicinoid compounds. The method of generating smoke comprises initiating a frontal polymerization reaction by heating a composition comprising a monomer compound that exothermically polymerizes upon initiation with an initiator compound and an initiator compound that initiates polymerization of the monomer compound present at a mass concentration that is at least five percent of the mass concentration of the monomer compound. The polymerization of the monomer compound is exothermic, and in one embodiment the concentration of initiator compound is at least five percent of the concentration of monomer compound. The smoke mainly comprises thermal decomposition products of the initiator compound.

Abstract: The invention relates to a method for preferably adiabatic nitration of nitratable aromatic organic compounds (aromatics) and to a corresponding plant, in particular a production plant (nitration plant) for carrying out said method.

Abstract: A method of autothermal oxidative coupling of methane (OCM) utilizes introducing a methane-containing feedstock and an oxygen-gas-containing feedstock into a reactor (10) as a flowing mixture (18) with a space time of 500 ms or less. The reactor (10) contains a catalyst bed (20) of an OCM catalyst that contacts the flowing mixture and wherein the catalyst bed (20) has a heat Peclet number (Peh) of from 5 or less, a mass Peclet number (Pem) of from 5 or more, and a transverse Peclet number (P) of from 1 or less while contacting the flowing mixture. The methane and oxygen of the feedstocks are allowed to react within the reactor (10) to form methane oxidative coupling reaction products. A reactor (10) for carrying out the OCM reaction is also disclosed.

Abstract: The present disclosure provides a process for producing trifluoroiodomethane by reacting trifluoroacetic acid, an iodine source, and a metal fluoride in the presence of a metal catalyst to produce trifluoroiodomethane.

Abstract: The present disclosure provides a process for producing trifluoroiodomethane. The process includes providing a metal trifluoroacetate, an iodine source, a metal catalyst, and a solvent, and reacting the metal trifluoroacetate and the iodine source in the presence of the metal catalyst and the solvent to produce trifluoroiodomethane. The metal catalyst includes at least one selected from the group of ferrous chloride and zinc (II) iodide.

Abstract: The present disclosure provides a method for purifying trifluoroiodomethane. The method includes providing a process stream comprising trifluoroiodomethane, organic impurities, and acid impurities; reacting the process stream with a basic aqueous solution, the basic aqueous solution comprising water and at least one base selected from the group of an alkali metal carbonate and an alkali metal hydroxide; and separating at least some of the organic impurities from the process stream.

Abstract: The present invention relates to a two-stage hydroformylation process for producing pound of the formula (I) and to a process for producing a compound of the formula (V) comprising the two-stage hydroformylation process for producing a compound of the formula (I) followed by hydrogenation of the compound of the formula (I).

Abstract: In a process for the oxidation of a lower alkane, such as methane, over a catalyst containing Cu and one or more zeolite or zeotype materials, the oxidation is conducted in the presence of ammonia in the feed gas at a process temperature below 350° C. The oxidation can be performed in a continuous process.

Abstract: A method for manufacturing calcium diglyceroxide crystals includes at least the following steps: placing at least one calcium element source compound, in particular calcium oxide, in suspension in glycerol or in a homogeneous mixture of glycerol and an anhydrous solvent of glycerol, in particular methanol, referred to as the “starting suspension”, the molar ratio being greater than or equal to 2; milling the starting suspension at an ambient temperature of less than or equal to 50° C. in a three-dimensional liquid-phase ball mill for a holding time of 15 minutes or less; recovering, at the outlet of the mill, a suspension of calcium diglyceroxide crystals, and optionally, washing the obtained suspension with a glycerol solvent in order to eliminate any excess glycerol, optionally, drying the suspension of calcium diglyceroxide crystals so as to obtain a powder of calcium diglyceroxide crystals. Also disclosed are uses associated with the calcium diglyceroxide crystals.

Abstract: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.

Abstract: The present invention provides an efficient process for the isolation of natural crystallized thymol product derived from crude natural Monarda citriodora (Jammu Monarda) oil useful for incorporation into foods and beverages in amounts due to strong antimicrobial, antibacterial, antioxidant properties as well as for use as a preservative. The recovery of crystallized thymol product obtained is more than 72% from Hexane-Jammu Monarda oil in a ratio 1:1 under specific conditions. A method for preparing natural thymol in crystal form involves providing crude Jammu Monarda oil in a Flask and gradually reducing the temperature of the flask containing Monarda oil:Hexane in a step-wise manner, thereby producing highly pure crystals (?95.5%) within 48 h. The methods disclosed herein are suitable for pharmaceutical GMP.

Abstract: Methods for manufacturing phenoxyethanol from a reaction of a phenolate with a monohalohydrin. The phenolate is reacted with the monohalohydrin at a reaction temperature that is less than or equal to a boiling point of a reaction mixture to produce products that include the phenoxyethanol.

Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.

Abstract: Disclosed are a process for abating 3-cyclohexenone from a feed mixture comprising 3-cylclohexenone and cyclohexanone, comprising a hydrogenation step of contacting the feed mixture with hydrogen in the presence of a hydrogenation catalyst under hydrogenation conditions to obtain a hydrogenated mixture, cyclohexanone-containing products comprising 3-cyclohexenone and/or 2-cyclohexenone at low concentrations, and compositions of matter useful for making such cyclohexanone-containing products, particularly by using such processes.

Abstract: The present invention relates to a method for the purification of natural vanillin, comprising a step involving the stripping of a liquid flow F2 containing natural vanillin. The invention also relates to the natural vanillin that can be obtained using the method of the invention, as well as a device for purifying natural vanillin.

Abstract: This disclosure provides routes of synthesis of acrylic acid and other ?,?-unsaturated carboxylic acids and their salts, including catalytic methods. In an aspect, there is provided a process for producing an ?,?-unsaturated carboxylic acid or a salt thereof, the process comprising: (1) contacting in any order a group 8-11 transition metal precursor compound comprising at least one first ligand, at least one second ligand, an olefin, carbon dioxide, a diluent, and an anionic polyaromatic resin with associated metal cations to provide a reaction mixture; and (2) applying conditions to the reaction mixture suitable to produce the ?,?-unsaturated carboxylic acid or a salt thereof. Methods of regenerating the polyaromatic resin with associated metal cations are described.

Abstract: Non-water soluble cannabinoid acids are isolated from trichomes and flower of Cannabis genus by leaching with alkaline water. The leaching with alkaline water converts the cannabinoid acids to water soluble salts. The resulting solution of cannabinoid salts may be used as a source of acidic cannabinoids for pharmaceutical applications or the cannabinoid acid salts may be converted back to their acid form and precipitated into a high purity microcrystalline powder by acidification of the aqueous solution. Compounds that are not water soluble and do not form salts in alkaline water such as many pesticides, fungicides and off flavors will not be concentrated.

Abstract: A process for continuously preparing a butyl acrylate H2C?CH—C(?O)OR, with R=n-butyl or isobutyl, wherein aqueous 3-hydroxypropionic acid is converted under dehydrating and esterifying conditions in the presence of the corresponding butanol R—OH in a reactor with a rectification column and butyl acrylate formed, unconverted butanol and water used and formed are distilled off overhead as a ternary azeotrope, after separation into a liquid aqueous phase and liquid organic phase each of the aqueous and organic phases is at least partly discharged, and the organic phase comprising the butyl acrylate and the butanol is subjected to distillative separation.

Abstract: The invention includes methods and materials for forming and manipulating aromatic-based polymers and copolymers using biomass compounds as starting materials. Embodiments of the invention can be used in processes designed to replace those used in the petro-chemical industry. Typical embodiments of the invention include methods and materials for forming and/or modifying compounds including dicarboxylic acid ester dimers, benzoxazines and dicarboxylic acid ether dimers. Embodiments of the invention further provide methods and materials for utilizing these compounds to form commercially desirable polymers having structures and physical properties akin to those found in polymers formed from petroleum products.

Abstract: A method for co-production of high purity dimethyl carbonate and mono-ethylene glycol by applying a reactor, such as a membrane reactor and/or an adsorbent-catalytic reactor by capturing and reacting carbon dioxide with methanol and ethylene oxide. Carbon dioxide may be recovered from primary sources (utilities and industrial processes) by a membrane or solid adsorbent, and subsequently converted to an intermediate hydroxy-ethyl-methyl carbonate by reacting with ethylene oxide and methanol. For high-purity carbon dioxide (obtained by carbon capture technologies or from an ethanol fermentation process), the membrane reactor is replaced with a catalytic reactor for direct conversion of carbon dioxide to hydroxy-ethyl-methyl carbonate by reacting with ethylene oxide and methanol. The hydro-ethyl-methyl carbonate is further reacted with methanol for conversion to dimethyl carbonate. A combination of heterogeneous and homogeneous catalysts is implemented for an effective conversion of carbon dioxide.

Abstract: Methods and compositions comprising an emulsion or a microemulsion for use treating an oil and/or gas well are provided. In some embodiments, the emulsion or the microemulsion comprises an aqueous phase, a solvent, a surfactant comprising alkyl polyglycoside, an alcohol, and, optionally, one or more additives.

Abstract: Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

Abstract: The present invention relates to an adamantane derivative compound and an organic light-emitting diode (OLED) including the same, and more particularly, to an adamantane derivative compound capable of being used in an OLED and an OLED having excellent properties such as low voltage and high efficiency using the compound.

Abstract: The present invention is directed to compounds and methods that inhibit the cytosolic form of BCAT1.

Abstract: The present invention relates to a method for preparing an aliphatic isocyanate capable of suppressing the occurrence of side reactions and the production of by-products. The method for preparing an aliphatic isocyanate comprises a step of reacting a salt of an aliphatic amine with phosgene, wherein the reaction step comprises a first reaction step in which phosgene is primarily added and reacted with the salt of an aliphatic amine salt at a temperature of 80 to 100° C., and a second reaction step in which phosgene is secondarily added and reacted with the resultant product of the first reaction step at a temperature of 120 to 160° C., and wherein the amount of the primarily added phosgene is a certain ratio of the total amount of the phosgene.

Abstract: Disclosed herein is a continuous manufacturing process for lomustine that has a short residence time and 63 percent yield. Major advantages of this process are that the total production cost for lomustine is lower, the product is higher quality, and the manufacturing operation is safer for production personnel.

Abstract: Described herein is a linking agent that includes a polymeric or non-polymeric core molecule and one or more photoreactive groups covalently attached to the core molecule by one or more linking elements that include a urea linkage, a carbamate linkage, or a combination thereof.

Abstract: Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

Abstract: Newly synthesized derivatives of BAS00127538 have been discovered to possess antibiotic activity and to combat resistant bacterial strains. Compounds and pharmaceutical compositions containing these compounds are described, and are based on a genetic scaffold structure. Synthetic methods and methods of using the compounds also are described. Preferred compounds bind to Lipid II with high affinity, have markedly reduced cytotoxicity compared to BAS00127538, and retain activity against drug-resistant strains of Enterococci. They are stable in plasma, have dramatically improved pharmacokinetic and pharmacodynamics properties, and possess in vivo efficacy in a mouse model of sepsis.

Abstract: There are provided compounds of formula I, wherein R1A to R1E, R2 to R4, R5a, L and X1 to X3 have meanings given in the description, which compounds have anti-inflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

Abstract: The present invention relates to crystalline forms of mesaconine. Specifically, the present invention relates to crystalline form A, crystalline form B and crystalline form C of mesaconine and preparation methods thereof. In the method, the mesaconine is crystallized in solvent, and then the crude crystal is dried to obtain target crystalline form. The crystalline forms of mesaconine according to the present invention have good solubility, good stability, low hygroscopicity, long-term storage capability and good reproducibility, and have a good prospect to be developed as pharmaceuticals.

Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory conditions, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering a compound of the invention.

Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

Abstract: A method of preparing an imidazolin-2-tones compound includes: dissolving a cycloheptatrienone and an aromatic isocyanate in a solvent; and reacting the cycloheptatrienone and the aromatic isocyanate in the solvent without an oxidant and a catalyst to obtain the imidazolin-2-tone compound.

Abstract: A compound having the formula (I): is disclosed. A method of preparing the compound of formula (I) is also disclosed.

Abstract: The present invention refers to compounds endowed with RNA helicase DDX3 inhibitory activity of formula I and II and their therapeutic use, in particular for the treatment of viral diseases.

Abstract: The present invention relates to diaminotriazine compounds of the formula (I) and to their use as herbicides. The present invention also relates to agrochemical compositions for crop protection and to a method for controlling unwanted vegetation. wherein q is 0, 1, 2 or 3 Ra is selected from the group consisting of C1-C6-haloalkoxy, C1-C6-haloalkylthio, (C1-C6-haloalkyl)sulfinyl, (C1-C6-haloalkyl)-carbonyl, etc.; Rb is selected from the group consisting of halogen, OH, CN, amino, NO2, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C1-C6-alkoxy, etc.; R1 is selected from the group consisting of H, OH, S(O)2NH2, CN, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, (C3-C6-cycloalkyl)-C1-C4-alkyl, etc.; R2 is selected from the group consisting of H, OH, S(O)2NH2, CN, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, (C3-C6-cycloalkyl)-C1-C4-alkyl, etc.; R3 is selected from the group consisting of H, halogen, OH, CN, C1-C6-alkyl, (C1-C6-alkoxy)-C1-C6-alkyl, C3-C6-cycloalkyl, etc.

Abstract: The present invention relates to a triazine precondensate according to the general formula (I) where R1 means Q1 or a moiety of the formula R3—N—R4 connected with the nitrogen atom to the triazine ring of the structure of formula (I), where R9 means Q1 or a moiety of the formula R7—N—R8 connected with the nitrogen atom to the triazine ring of the structure of formula (I), where R2, R3, R4 and R6 mean independently from each other H, Q1 or (i), R7 and R8 mean independently from each other H, Q1, (ii) or (iii) or (i), R10 and R11 mean independently from each other R7 or R8; R5 means linear or branched C2-C20-alkyl that can be interrupted by one or more oxygen atoms, sulphur atoms, substituted or non-substituted nitrogen atoms.

Abstract: The present invention provides methods for the preparation of compounds useful in in vivo therapeutic and diagnostic applications. In particular, the present invention provides a method for the synthesis of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and also methods for the preparation of metal chelates of DOTA.

Abstract: Peroxisome proliferator activated receptor (PPAR) compounds, and methods of using the same for treating bone fractures, treating osteoporosis and/or metabolic bone diseases, and inducing osteogenesis and/or chondrogenesis, are disclosed.

Abstract: The present invention includes novel bridged bicycloalkyl-substituted aminothiazole compounds useful in preventing or treating cancer in a subject in need thereof. The present invention also includes methods of preventing or treating cancer in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention.

Abstract: The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activity. The invention also relates to pharmaceutical compositions comprising these compounds and to the use of these compounds in the treatment of cardiovascular diseases, fatty acid metabolism and glucose utilization disorders, gastrointestinal diseases and liver diseases.

Abstract: The present invention describes thymoquinone compounds formula (I): (i) These compounds have been identified as being useful in the treatment of cancer.